GlassScriptPhysician profile
Derek J Heard
NPI 1215921176
$10,294.94
in general payments reported to CMS, 2019-2025
45 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,392 · 2020: $1,427 · 2021: $1,636 · 2022: $1,392 · 2023: $1,483 · 2024: $908 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,434 · Entertainment: $13.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,433.99 |
| Entertainment | $13.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,323.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,038.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $963.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $857.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $783.40 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $715.06 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $629.93 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.42 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $471.53 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $338.91 | 2019-2025 | Verquvo, Capvaxive, Belsomra |
| Novartis Pharmaceuticals Corporation | $227.28 | 2019-2023 | |
| Abbvie INC. | $206.21 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $191.47 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $170.09 | 2019-2023 | |
| Amarin Pharma, INC. | $167.90 | 2020-2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $164.96 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.84 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $127.65 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Ironwood Pharmaceuticals, INC | $107.63 | 2020-2024 | Linzess |
| Ironshore Pharmaceuticals INC. | $101.31 | 2019 | |
| Abbott Laboratories | $98.50 | 2022-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $93.12 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $86.55 | 2019-2024 | Eliquis |
| Biogen, INC. | $80.43 | 2021 | |
| Dexcom, INC. | $69.71 | 2024-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $67.73 | 2020 | |
| Paratek Pharmaceuticals, INC. | $62.50 | 2023-2024 | Nuzyra |
| Organogenesis INC. | $54.94 | 2022-2025 | Puraply, Apligraf |
| Sanofi Pasteur INC. | $50.62 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $50.61 | 2024-2025 | Voquezna |
| Global Blood Therapeutics, INC. | $46.74 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.89 | 2019 | |
| Genentech USA, INC. | $38.53 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.22 | 2022 | |
| Celgene Corporation | $22.59 | 2019 | |
| Inspire Medical Systems, INC. | $19.73 | 2025 | Inspire |
| Medtronic, INC. | $18.56 | 2023 | Minimed 780g |
| Esperion Therapeutics, INC. | $17.67 | 2025 | Nexletol |
| Exact Sciences Corporation | $16.63 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $16.34 | 2021 | |
| Shield Therapeutics INC | $16.06 | 2022 | |
| Corium, LLC | $15.39 | 2023 | Adlarity |
| Mallinckrodt Enterprises LLC | $13.67 | 2019 | |
| Optos, INC. | $13.50 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Corcept Therapeutics | $12.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Heard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.